Retinoblastoma expression in thyroid neoplasms

Modern Pathology

Volumn 13, Issue 5, 2000, Pages 562-569

  Anwar, Faten ^a   Emond, Mary J ^a   Schmidt, Rodney A ^a   Hwang, Harry C ^a   Bronner, Marry P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Immunohistochemistry; Nodular goiter; Paraffin embedded tissue; Retinoblastoma; Thyroid neoplasm

Indexed keywords

ARTICLE; CANCER INVASION; CELL CYCLE S PHASE; EPITHELIUM CELL; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NODULAR GOITER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; THYROID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0034118060     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880097     Document Type: Article

References (45)

1. Knudson AG Jr. The genetics of childhood cancer. Cancer 1975;35(Suppl 3):1022-6.
2. Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci 1975;72(12):5116-20.
3. Knudson AG Jr, Meadows AT, Nichols WW, Hill R. Chromosomal deletion and retinoblastoma. N Engl J Med 1976; 295(2):1120-3.
4. Lee W-H, Shew J-Y, Hong FD, Sery TW, Donoso LA, Young LJ, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642-6.
5. Lai A, Marcellus RC, Corbeil HB, Bronton PE. RBP1 induces growth arrest by expression of E2F-dependent transcription. Oncogene 1999;18(12):2091-100.
6. Brown VD, Philips RA, Gallie BL. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol 1999;19(5):3246-56.
7. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 1993;13(10):6501-8.
8. Rubin E, Tamrakar S, Ludlow JW. Protein phosphatase type 1, the product of retinoblastoma susceptibility gene, and cell cycle control. Front Biosci 1998;3:D1209-19.
9. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T. Loss of E2F1 reduces tumorigenesis and extends the life span of Rb (±) mice. Nat Genet 1998;18(4):360.
10. Shew JY, Ling N, Yang XM, Fodstadt O, Lee WH. Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (PP 1109 (Rb)) in osteosarcomas and synovial sarcomas. Oncogene Res 1989;4:205-14.
11. Cance WG, Brennan MF, Dudas ME, Huang C-M, CordonCardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990;323:1457-62.
12. Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (P16 INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13(5):1065-72.
13. Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, et al. Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science 1988;242:1563-6.
14. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-6.
15. Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee W-H. Suppression of tumorigenicity of human prostatic carcinoma cells by replacing a mutated RB gene. Science 1990;247: 712-5.
16. Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BAJ, Tang A, et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. Oncogene 1989;4:725-9.
17. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 1991;51:2735-9.
18. Cagle PT, El-Naggar AK, Xu HJ, Hu SX, Benedict WF. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol 1997;150(92):393-400.
19. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with P16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999;18(5):1197-203.
20. Horowitz JM, Park S-H, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci 1990;87:2775-9.
21. Frauman AG, Moses AC. Oncogenes and growth factors in thyroid carcinogenesis. Endocrinol Metab Clin North Am 1990;19:479-93.
22. Aasland R, Lillehaug JR, Male R, Josendal O, Arhaug JE, Kleppe K. Expression of oncogenes in thyroid tumors: coexpression of C-erbB2/neu and C-erb B. Br J Cancer 1988; 57:358-63.
23. Wyllie FS, Lemoine NR, Williams ED, Wynford-Thomas D. Structure and expression of nuclear oncogenes in multistage thyroid tumorigenesis. Br J Cancer 1989;60:561-5.
24. Namba H, Rubin SA, Fagin J. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474-9.
25. Lemoine NR, Mayal ES, Wyllie FS, Williams ED, Goyns M, Stringer B, et al. High frequency of oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4: 159-64.
26. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA. Mice deficient in both P53 and Rb develop tumors primarily of endocrine origin. Cancer Res 1995;55(5):1146-51.
27. Holm R, Nesland JM. Retinoblastoma and P53 tumor suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172(3):267-72.
28. Soares P, Cameselle-Teijeiro J, Sobrinho-Simoes M. Immunohistochemical detection of P53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 1994;24(3):205-10.
29. Figge J, Bakst G, Weisheit D, Solis O, Ross JS. Image analysis quantitation of immunoreactive retinoblastoma protein in human thyroid neoplasms with a streptavidin-biotin peroxidase staining technique. Am J Pathol 1991;139(6):1213-9.
30. Zou M, Shi Y, Farid NR, Al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine 1998;8(1):61-4.
31. Holm R, Nesland JM. Retinoblastoma and P53 tumor suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172(3):267-72.
32. Geradts J, Kratzke RA, Crush-Atanton S, Shu Fen Wen, Lincoln CE. Wild type and mutant retinoblastoma protein in paraffin sections. Mod Pathol 1996;9:339-47.
33. Geradts J, Hu S-X, Lincoln CE, Benedict WF, Xu H-J. Aberrant Rb gene expression in routinely processed, archival tumor tissues determined by three different anti-Rb antibodies. Int J Cancer 1994;58:161-7.
34. Kashima K, Yokoyama S, Daa T, Nakayama I, Nickerson PA, Noguchi S. Cytoplasmic biotin like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. Mod Pathol 1997;10:515-9.
35. LiVolsi VA, Merino MJ. Histopathologic differential diagnosis of the thyroid. Pathol Annu 1981;16(Pt 2):357-406.
36. LiVolsi VA. Surgical pathology of the thyroid. In: Zorab R, Bennington JL, editors. Major problems in pathology. Vol. 22. 1st ed. Philadelphia: W.B. Saunders; 1990. p. 131-323.
37. Agresti, A. Categorical data analysis. New York: John Wiley & Sons; 1990, p. 48-49, 249-250.
38. Gabriel, KR. Simultaneous test procedures for multiple comparisons on categorical data. J Am Stat Assoc 1966;61:1081-96.
39. Miettinen M, Karkkainen P. Differential HBME-1 reactivity in benign versus malignant thyroid tissue is helpful in the diagnosis of thyroid tumors [abstract]. Mod Pathol 1995;9: 50A.
40. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumors: preferential reactivity with malignant tumors. Virchows Arch Int J Pathol 1996;429:213-9.
41. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147(3):815-22.
42. LiVolsi VA, Merino MJ. Worrisome histologic alterations following fine-needle aspiration of the thyroid (WHAFFT). Pathol Ann 1994;29(Pt 2):99-120.
43. Xu H-J, Hu S-X, Benedict WF. Lack of nuclear Rb protein staining in GO/middle G1 cells: correlation to changes in total Rb protein level. Oncogene 1991;6:1139-46.
44. Bronner MP. Hürthle cell lesions of the thyroid. Pathol Case Rev 1997;2:200-9.
45. Harlow SP, Duda RB, Bauer KD. Diagnostic utility of DNA content flow cytometry in follicular neoplasms of the thyroid. J Surg Oncol 1992;50(1):1-6.